About Us

DailyRx.com strives to provide accurate and timely health news to our readers.  The following is our policy regarding corrections submissions.

All DailyRx.com news articles are independently written, reflecting a sound editorial policy free from outside influences or bias. DailyRx.com does accept advertising and derives revenue from clients who subscribe to the news service and eNewsletter programs.

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study of Liver Disease’s (AASLD) Liver Meeting 2008 in San Francisco.

dailyRx knows your personal privacy is very important, and we intend to earn your trust each and every day you access dailyRx.com. Our privacy policy applies to all dailyRx-owned and -operated services, but it does not apply to third-party companies or for advertising relationships. Each of these companies has its own privacy policies, and we strongly encourage you to review the policies of each and every Web site you visit, are directed to or register for.